902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II

Estimated total cost of care and patient out-of-pocket cost savings

Cost effectiveness of CAR T cell therapy compared to bispecific T cell engagers in Relapsed Refractory multiple myeloma A retrospective study using a markov model

Characteristics epidemiology and outcomes of post transplant lymphoproliferative disorders associated hospitalizations A 2016 2022 national inpatient sample analysis

Beyond approval Lymphoma drugs and real world representation 2015–2025

Measuring patient preference information for blood cancer treatments and outcomes A systematic review and meta analysis

Geriatric hematologic care in Latin America Results from a regional survey of hematology centers

A discrete choice experiment DCE to determine preferences for relapsed refractory follicular lymphoma R R FL treatment attributes among patients and physicians in the USA

Willingness to pay for DLBCL treatment characteristics in Japan

Cumulative cardiac risk strongly predicts in hospital mortality and cost burden in patients hospitalized with chronic lymphocytic leukemia A national inpatient analysis 2020–2022

Experiences of patients with multiple myeloma enrolled in high deductible health plans A mixed methods study

Parental perspectives on financial distress during treatment for childhood acute lymphoblastic leukemia A qualitative report from Children s oncology group COG study ACCL20N1CD

Real world healthcare resource utilization HCRU following CAR T cell therapy in US patients treated in newly authorized treatment centers

Representation of older adults in registrational trials associated with therapeutic approvals in follicular lymphoma

Cost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance

Quality and timing of patient reported outcome reports in randomized controlled trials RCTs of patients with lymphoid malignancies Analysis of 83 RCTs published between 2015 and 2025

Racial disparities in inpatient outcomes and resource utilization in multiple myeloma An NIS based analysis 2016–2022

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia CLL in Japan

Identifying barriers to clinical trial enrollment for children with relapsed or refractory hematologic malignancies

Real world utilization patterns of bone modifying agents for multiple myeloma in the era of novel therapies

Early methotrexate level thresholds predictive of acute kidney injury in patients with b cell lymphomas receiving high dose methotrexate

Understanding the burden and predictors of 90 day all cause readmissions following hospitalization for diffuse large B cell lymphoma An analysis of the nationwide readmissions database